


# **Eukaryotic Gene Expression: Basics & Benefits**

**P N RANGARAJAN**

## **Lecture 20**

**Regulation of gene expression by cytokines**

Lectures 15-19



How cytokines regulate gene expression?

## What are cytokines?

Cytokines are proteins produced by diverse cell types and they primarily interact with cells of the immune system in order to regulate the body's response to disease and infection.

Cytokines also regulate several normal cellular processes in the body.

## Types of Cytokines

Cytokines are a diverse group of molecules:

- colony stimulating factors (stimulate production of blood cells)
- growth and differentiation factors (function primarily in development)
- immunoregulatory and proinflammatory cytokines (interferons, interleukins and TNF- $\alpha$  that function in the immune system)

## How Cytokines Work

Cytokines are released by various cell types cells into the circulation or directly into tissue.

The cytokines locate target immune cells and bind to specific cell surface receptors on the target immune cells.

The cytokine-cytokine receptor interaction activates specific signal transduction pathways leading to the modulation of activity of a number of proteins including transcription factors ultimately leading to distinct physiological responses.

## Cytokines and their functions

**IL-1** activates Antigen Presenting Cell and CD4+ lymphocytes; affect the differentiation of the B-Cells and T-Cells and other immunocompetent cells and takes part in the regulation of productions of other cytokines and GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor)

**IL-2** stimulates the proliferation and activation of B-Cells and T-Cells. IL-4 plays a role in the differentiation of TH2 (T Helper Type-2), in allergic responses, and in the switching of antibody types.

**IL-5** stimulates the production and maturation of eosinophils during inflammation.

**IL-8** acts as a chemotactic factor that attracts neutrophils, basophils and T-Cells to sites of inflammation.

**IL-12** is a critical linker between the innate immunity and adaptive immunity, capable of TH1 (T Helper Type-1) differentiation and IFN-Gamma release by T-Cells and NK cells.

## Cytokines and their functions

**IL-10** acts to repress secretion of pro-inflammatory cytokines.

**IL-3** is a poly potent activator of the hemopoietic cells. It stimulates NK-Cells and acts as a synergist with IL-4 during the induction of CD4+ lymphocyte activation process.

**IL-7** is known as the growth factor of the immature B-Cells and T-Cells. It induces apoptosis of tumor cells and causes differentiation of cells from a subgroup of acute myeloblastic leukemia.

**IL-9** stimulates the excretion of IL-2, IL-4, IL-6, IL-11, and takes part in a stimulation of cytotoxicity of T-killers and NK-Cells, inducing apoptosis.

**IL-11** is a pro-inflammatory factor, which regulates the functions of B-Cells and T-Cells. It also takes part in the induction of various killer cells' activities and acts as an autocrine factor for the proliferation of megacaryocytes.

## Cytokines and their functions

The secretion of **TNF-Alpha and TNF-Beta** by TH1 cells activates macrophages, inhibits apoptosis of neutrophils and eosinophils, and induces vascular endothelial cells at the sites of infection to change the adhesion molecules they express so phagocytes circulating in the blood can bind to them

**IFN-Alpha, IFN-Beta and IFN-Gamma** are produced in the area of infection during the early phase of immune response.

**IFN-Alpha and IFN-Beta** induce proliferation of NK-Cells and stimulate innate and adaptive immune responses that are specifically targeted to virus infections.

Upon activation, NK cells release **IFN-Gamma**, which activates macrophages to secrete cytokines that help to activate macrophages to secrete cytokines that help to activate T-Cells and promote the initiation of T-Cell responses.

## **Cytokines are key regulators of immune functions**

They alter gene expression and promote cell growth

They either boost ( IL-2) or suppress (i.e., IL-10, and TGF $\beta$ 1) immunity

Type I IFN and TNFa are mediators of natural/innate immunity

IL-2, IL-4, IL-5, IL-12, IL-1 are regulators of lymphocytic growth, activation and differentiation

IFN g is an activator of inflammatory cells

IL-3, GM-CSF, IL-7 stimulate hematopoiesis



## **Overproduction of Cytokines**

Overproduction or inappropriate production of certain cytokines by the body can lead to diseases.

For example, in case of rheumatoid arthritis, cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) are produced in excess and these leads to inflammation and tissue destruction.

IL-4 causes allergic diseases

IL-17 causes autoimmune diseases

**A number of drugs have been developed which  
act by inhibiting the action of cytokines**

**Kineret (anakinra)**

Used in the treatment of rheumatoid arthritis.  
It works by inhibiting IL-1 binding to its receptor.

**Enbrel (etanercept)  
Remicade (infliximab)  
Humira (adalimumab)**

These are TNF-alpha inhibitors (*a.k.a.* TNF blockers)

They bind TNF and prevent TNF from binding to cell surface receptors.

**How do these cytokines act?**

**The first step in Cytokine action**

**is their binding to cytokine receptors**

**CYTOKINE RECEPTORS**

# Cytokine Receptors

- Type I
- Type II
- Soluble

## **Type I cytokine receptors**

Type 1 interleukin receptors  
Erythropoietin receptor  
GM-CSF receptor  
G-CSF receptor  
Growth hormone receptor  
prolactin receptor  
Oncostatin M receptor  
Leukemia inhibitory factor receptor

## **Type II cytokine receptors**

Type II interleukin receptors  
Interferon-alpha/beta receptor  
Interferon-gamma receptor

## **Immunoglobulin superfamily**

Interleukin 1 receptor  
CSF1  
C-kit receptor  
Interleukin-18 receptor

**Tumor necrosis factor receptor family**

CD27  
CD30  
CD40  
CD120  
Lymphotoxin beta receptor

**Chemokine receptors**

Interleukin-8 receptor  
CCR1  
CXCR4  
MCAF receptor  
NAP-2 receptor

**TGF beta receptors**


TGF beta receptor 1  
TGF beta receptor 2

## Type I cytokine receptors

These are transmembrane receptors expressed on the surface of cells that recognize and respond to cytokines with four  $\alpha$ -helical strands.

They share a common amino acid motif (WSXWS) in the extracellular portion adjacent to the cell membrane.

Members of the type I cytokine receptor family comprise different chains, some of which are involved in ligand/cytokine interaction and others that are involved in signal transduction.



## Type II cytokine receptors

These are transmembrane proteins that are expressed on the surface of certain cells, which bind and respond to a select group of cytokines.

These receptors are similar to type I cytokine receptors **except they do not possess the signature sequence WSXWS that is characteristic of type I receptors.**

The intracellular domain of type II cytokine receptors is typically associated with a tyrosine kinase belonging to the Janus kinase (JAK) family.



## Type I cytokine receptors

### **Interleukin receptors**

Interleukin-2 receptor  
Interleukin-3 receptor  
Interleukin-4 receptor  
Interleukin-5 receptor  
Interleukin-6 receptor  
Interleukin-7 receptor  
Interleukin-9 receptor  
Interleukin-11 receptor  
Interleukin-12 receptor  
Interleukin-13 receptor  
Interleukin-15 receptor  
Interleukin-21 receptor  
Interleukin-23 receptor  
Interleukin-27 receptor

### **Colony stimulating factor receptors**

Erythropoietin receptor  
GM-CSF receptor  
G-CSF receptor

### **Others**

growth hormone receptor  
prolactin receptor  
Oncostatin M receptor  
Leukemia inhibitory factor receptor

## Type II cytokine receptors

### **Interferon receptors**

interferon-alpha/beta receptor  
interferon-gamma receptor

### **Interleukin receptors**

Interleukin-10 receptor  
Interleukin-20 receptor  
Interleukin-22 receptor  
Interleukin-28 receptor

**Once the cytokine binds to its receptor  
what happens?**

**Cytokine signal transduction pathways**


## THE JAK-STAT PATHWAY

The cytokine receptors lack catalytic domains (unlike RTKs).

On binding to cytokines, they interact with members of a unique the family of cytoplasmic protein tyrosine kinases known as the **Janus kinases (JAKs)**.


**JAKs** physically associate with the membrane-proximal region of the ligand-bound receptor, leading to their tyrosine phosphorylation and activation.

The activated JAKs phosphorylate the receptors as well as cytoplasmic proteins belonging to a family of transcription factors called the **signal transducers and activators of transcription (STATs)**, providing a novel signaling pathway that is shared by all members of the cytokine receptor superfamily.




Adapted from: [http://en.wikipedia.org/wiki/File:Jakstat\\_pathway.svg](http://en.wikipedia.org/wiki/File:Jakstat_pathway.svg)

**Growth factor signalling  
(RTKs)**



**Receptor becomes  
tyrosine kinase**

**Cytokine signalling  
(JAK-STAT)**



**Receptor becomes docking  
site for tyrosine kinases**

## **JANUS KINASES**

JAK belongs to a family of non-receptor protein tyrosine kinases of approximately 130 kDa, comprising of **JAK1, JAK2, JAK3** and **TYK2 (non-receptor Protein Tyrosine Kinase-2)**.

## **STATs**

There are seven STAT proteins:

STAT1 to 6, including STAT5a and STAT5b, which are encoded by distinct genes.

**Cytokine receptor****Janus kinases****STATs****IFN- $\gamma$** **JAK1 and JAK2****Stat1****IFN- $\alpha/\beta$** **JAK1 and Tyk-2\*****Stat2****IL-2****JAK1 and JAK3****Stat5****IL-3****JAK2****Stat5****IL-4****JAK1 and JAK3****Stat6****IL-6****JAK1 (and sometimes others)****Stat3****IL-10****JAK1 and Tyk-2****Stat3****IL-12****JAK2 and Tyk-2****Stat4**

**Interferon alpha signalling**

**Interferon alpha receptors**

**Activation of Jak1-Tyk2**

**STAT1-STAT2 heterodimerization**

**Transcriptional activation**

**Interferon gamma signalling**

**Interferon gamma receptors**

**Activation of Jak1- Jak2**

**STAT1-STAT1 homodimerization**

**Transcriptional activation**

## **STAT binding sites:**

### **ISRE (STAT1-2)**

Interferon Stimulated Response Element

**AGTTTNCNTTCC**

### **GAS (STAT1-5)**

*Interferon*-Gamma Activated Sequence

**TTCN3GAA**

### **STAT6**

**TTCN4GAA**



**Each of the seven STATs has separate *in vivo* functions,  
as revealed by knockout experiments.**

**STAT1 knockout mice have an impaired interferon signalling**


**STAT4 knockouts impaired IL-12 signalling,**

**STAT5a knockouts impaired prolactin signalling,**

**STAT5b knockouts impaired growth hormone signalling, and**

**STAT6 knockout impaired IL-4 and IL-13 signalling.**

# THE JAK-STAT PATHWAY





2009  
ProteinLounge.com

 SABiosciences™

IFN-  
Inducible  
Gene Expression

# THE JAK-STAT PATHWAY






# Growth hormone


2009  
ProteinLounge.com

SABiosciences™



Nmi, SOCS, BCL-XL, p21,  
Myc, Nos2,  
Gene Expression

# IL-2 Pathway



## The IL-2 receptor forms homo/heterodimers

Low affinity

$10^{-8}$ ,

expressed by activated T cells,

No function


Intermediate affinity

$10^{-9}$ , resting T cells.

High affinity

$10^{-11}$ , activated T cells


# JAK/STAT Pathway



Nmi, SOCS, BCL-XL-, p21,  
 Myc, Nos2,  
 Gene Expression



# IL-2 Pathway



## **Termination of Jak/STAT signaling**

### **1. Phosphatase**

**Receptor-Shp-1 (HCP, SH-PTP1, and PTP1c),  
Shp-2 (Syp and PTP1D), and SHIP**

**Nuclear phosphatase**

### **2. Suppressors of Cytokine Signaling**

**(SOCS). SOCS1-7.**

### **3. Degradation of Stats through**

**ubiquitination/proteasome pathway.  
The PIAS family**

**Alexander et. al. Annu. Rev. Immunol. 2004. 22:503**

## DRUGS

ENBREL	MAb AGAINST TNF $\alpha$ RECEPTOR	RHEUMATOID ARTHRITIS, CROHN'S DISEASE
INTRON A	INTERFERON A-2B	HEPATITIS C MELANOMA
EPOGEN	ERYTHROPOIETIN	STIMULATES RBC PRODUCTION

## DRUGS

ACTIMMUNE

INTERFERON  $\gamma$  1 $\beta$

CHROMING GRANULOMATOUS  
DISEASE

OSTEROPOROSIS

NEUPOGEN

G-CSF

STIMULATES PRODUCTION OF  
NEUTROPHILS

REDUCTION OF INFECTION IN  
CANCER PATIENTS UNDERGOING  
CHEMOTHERAPY

## DRUGS

LEUKINE

GM-CSF

STIMULATES PRODCUTION OF  
MYELOID CELLS AFTER  
BONE MARROW TRANSPLANTATION

NEUMAGA /  
NEULASTA

INTERLEUKIN 11

STIMULATES PRODUCTION OF  
PLATELETS

## REFERENCES

Ananthakrishnan R, Hallam K, Li Q, Ramasamy R.

[JAK-STAT pathway in cardiac ischemic stress.](#)

Vascul Pharmacol. 2005 Oct 28;

\

Walker JG, Smith MD.

[The Jak-STAT pathway in rheumatoid arthritis.](#)

J Rheumatol. 2005 Sep;32(9):1650-3.

Marrero MB.

[Introduction to JAK/STAT signaling and the vasculature.](#)

Vascul Pharmacol. 2005 Nov;43(5):307-9. Epub 2005 Nov 2.

Gao B.

[Cytokines, STATs and liver disease.](#)

Cell Mol Immunol. 2005 Apr;2(2):92-100.

Rani MR, Ransohoff RM.

[Alternative and accessory pathways in the regulation of IFN-beta-mediated gene expression.](#)

J Interferon Cytokine Res. 2005 Dec;25(12):788-98.

## REFERENCES

Best SM, Morris KL, Shannon JG, Robertson SJ, Mitzel DN, Park GS, Boer E, Wolfenbarger JB, Bloom ME.

[Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist.](#)

J Virol. 2005 Oct;79(20):12828-39.

JAK/STAT signal transduction: regulators and implication in hematological malignancies.

Biochem Pharmacol. 2006 Mar 14;71(6):713-21. Epub 2006 Jan 19.

Esper L, Dusanter-Fourt I, Chelbi-Alix MK.

[Negative regulation of the JAK/STAT: pathway implication in tumorigenesis](#)

Bull Cancer. 2005 Oct 1;92(10):845-57.

## REFERENCES

Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, Mattfeldt T, Barth TF, Moller P.

[Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.](#)

Oncogene. 2006 Mar 13;

Rakesh K, Agrawal DK.

[Controlling cytokine signaling by constitutive inhibitors.](#)

Biochem Pharmacol. 2005 Sep 1;70(5):649-57.

Poehlmann TG, Busch S, Mussil B, Winzer H, Weinert J, Mebes I, Schaumann A, Fitzgerald JS, Markert UR.

[The possible role of the Jak/STAT pathway in lymphocytes at the fetomaternal interface.](#)

Chem Immunol Allergy. 2005;89:26-35



## ACKNOWLEDGEMENT

**SA BIOSCIENCES  
Pathway Central**

[http://www.sabiosciences.com/pathway.php?sn=JAK\\_STAT\\_Pathway](http://www.sabiosciences.com/pathway.php?sn=JAK_STAT_Pathway)